Synergy to initiate Phase 3 plecanatide CIC trial in Q4

|About: Synergy Pharmaceuticals, Inc. (SGYP)|By:, SA News Editor

Synergy Pharmaceuticals (SGYP) completes an end-of-Phase 2 meeting with the FDA regarding plecanatide for the treatment of chronic idiopathic constipation.

The company and the regulator reach an agreement on the requirements and specifications for a Phase 3 pivotal program which will begin in Q4. (PR)

Shares +3.26% premarket.